Lilly Raises Profit Forecast on Amylin's $1.26B Payment

Source: Reuters, Toni Clarke and Esha Dey (8/9/12)

"Lilly plans to use the cash to advance its 'pipeline of more than 60 potential new medicines,' among other corporate uses."

Reuters, Toni Clarke and Esha Dey

Eli Lilly and Co (LLY.N) raised its 2012 net profit forecast for the second time in as many weeks to reflect an early payment of $1.26 billion from former partner Amylin Pharmaceuticals Inc, which has been acquired by Bristol-Myers Squibb Co (BMY.N).

Diabetes specialist Amylin had ended its decade-long partnership with Lilly in November. The companies were partners in marketing Amylin's diabetes drug Byetta and its longer-acting version, Bydureon. Bristol, which completed its Amylin purchase on Wednesday, has paid $1.7 billion apart from the cash consideration to cover Amylin's debt and its obligations to Eli Lilly.

Lilly plans to use the cash to advance its "pipeline of more than 60 potential new medicines," among other corporate uses. . .View Full Article

Cleantech Co. Wins PFAS Deal, Engineering Pact, Ships Clyra
Source: Richard Ryan (05/21/2026)

BioLargo (BLGO:OTCQX) shipped Clyra's first stocking order, signed Aquatech PFAS MOU, and won a US$1.2M engineering contract for a minerals processing facility, according to an Oak Ridge Financial research note

Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans
Source: Streetwise Reports (05/20/2026)

Keros Therapeutics Inc. (KROS:NASDAQ) lowered research spending & reported funding through 2028 as analysts monitor upcoming trial catalysts for ALS & Muscular Dystrophy drugs.

Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles
Source: Dr. Yun Zhong (05/20/2026)

Keros Therapeutics (KROS:NASDAQ) disclosed that initiation of its Phase 2 rinvatercept study in Duchenne muscular dystrophy will slip from 2Q26 to 3Q26 due to procedural regulatory delays, according to a Wedbush research note.

D. Boral Capital analyst Jason Kolbert reiterated his rating and price target on Coya Therapeutics Inc. (COYA:NASDAQ) following the company's receipt of FDA Fast Track Designation for COYA 302 in ALS.

California Biotech Co. Discovers VOXZOGO Breakthrough, Reports Strong Q1
Source: Streetwise Reports (05/11/2026)

BioMarin Pharmaceuticals Inc. (BMRN:NASDAQ) delivered positive long-term achondroplasia data alongside rising revenues, accelerating rare disease portfolio growth.